Pharmacokinetics of Alendronate

Abstract

Alendronate (alendronic acid; 4-amino-1-hydroxybutylidene bisphosphonate) has demonstrated effectiveness orally in the treatment and prevention of postmenopausal osteoporosis, corticosteroid-induced osteoporosis and Paget's disease of the bone. Its primary mechanism of action involves the inhibition of osteoclastic bone resorption. The pharmacokinetics and pharmacodynamics of alendronate must be interpreted in the context of its unique properties, which include targeting to the skeleton and incorporation into the skeletal matrix. Preclinically, alendronate is not metabolised in animals and is cleared from the plasma by uptake into bone and elimination via renal excretion. Although soon after administration the drug distributes widely in the body, this transient state is rapidly followed by a nonsaturable redistribution to skeletal tissues. Oral bioavailability is about 0.9 to 1.8%, and food markedly inhibits oral absorption. Removal of the drug from bone reflects the underlying rate of turnover of the skeleton. Renal clearance appears to involve both glomerular filtration and a specialised secretory pathway. Clinically, the pharmacokinetics of alendronate have been characterised almost exclusively based on urinary excretion data because of the extremely low concentrations achieved after oral administration. After intravenous administration of radiolabelled alendronate to women, no metabolites of the drug were detectable and urinary excretion was the sole means of elimination. About 40 to 60% of the dose is retained for a long time in the body, presumably in the skeleton, with no evidence of saturation or influence of one intravenous dose on the pharmacokinetics of subsequent doses. The oral bioavailability of alendronate in the fasted state is about 0.7%, with no significant difference between men and women. Absorption and disposition appear independent of dose. Food substantially reduces the bioavailability of oral alendronate; otherwise, no substantive drug interactions have been identified. The pharmacokinetic properties of alendronate are evident pharmacodynamically. Alendronate treatment results in an early and dose-dependent inhibition of skeletal resorption, which can be followed clinically with biochemical markers, and which ultimately reaches a plateau and is slowly reversible upon discontinuation of the drug. These findings reflect the uptake of the drug into bone, where it exerts its pharmacological activity, and a time course that results from the long residence time in the skeleton. The net result is that alendronate corrects the underlying imbalance in skeletal turnover characteristic of several disease states. In women with postmenopausal osteoporosis, for example, alendronate treatment results in increases in bone mass and a reduction in fracture incidence, including at the hip.

Healing properties of allograft from alendronate-treated animal in lumbar spine interbody cage fusion

“…The oral bioavailability of alendronate in the fasted state is about 0.7%. About 40-60% of the alendronate will deposit to bone [18]. Bisphosphonates bind to bone surfaces and subsequently inhibit osteoclast activ-224 ity, slowing down bone-turnover rate.…”

Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ)

“…However, not only are there direct inflammatory and necrotic effects on tissues exposed to N-BPs, but the bioavailability of N-BPs after oral administration is very poor. 96) Consequently, in patients with bone-metastatic tumours, N-BPs are administered mostly via intravenous drip. In osteoporotic patients, N-BPs must be taken, at the time of rising, together with 180 mL or more of water and the patient must avoid lying down for at least 30 min, as well as avoiding eating, drinking, or taking other drugs.…”

Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization

“…3,4 Bisphosphonates are eliminated mainly by urinary excretion of the unchanged drug, and they have very low oral bioavailability. 5,6 They also have side effects, including diarrhea, nausea, and vomiting. A particularly serious side effect of oral administration is esophageal inflammation or ulcers.…”